Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Therapy / Modality Type (mRNA-based Therapeutics, DNA / Plasmid DNA Therapeutics, siRNA (Small Interfering RNA), Antisense Oligonucleotides (ASOs), Gene Therapy Products, Others), By Service Type (Process Development & Optimization, Drug Product (Formulation, Fill & Finish), Analytical & Quality Control (QC) Services, Regulatory Support & Technology Transfer, Packaging & Fill–Finish Services), By Workflow Stage (Preclinical Development, Clinical Manufacturing (Phase I–III), Commercial-Scale Production), By End User, By Therapeutic Area, By Region and By Segments Forecasts, 2025-2034

Report Id: 1348 Pages: 185 Last Updated: 05 November 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation Of Nucleic Acid Therapeutics CDMO Market:

 Nucleic Acid Therapeutics CDMO Market By Therapy / Modality Type-

  •          mRNA-based Therapeutics
  •          DNA / Plasmid DNA Therapeutics
  •          siRNA (Small Interfering RNA)
  •          Antisense Oligonucleotides (ASOs)
  •          Gene Therapy Products
  •          Others

Nucleic Acid Therapeutics CDMO Market Seg

Nucleic Acid Therapeutics CDMO Market By Service Type-

  • Process Development & Optimization
    • cGMP Manufacturing
    • Drug Substance (API)
  • Drug Product (Formulation, Fill & Finish)
  • Analytical & Quality Control (QC) Services
  • Regulatory Support & Technology Transfer
  • Packaging & Fill–Finish Services

Nucleic Acid Therapeutics CDMO Market By Workflow Stage-

  • Preclinical Development
  • Clinical Manufacturing (Phase I–III)
  • Commercial-Scale Production

Nucleic Acid Therapeutics CDMO Market By End-User-

  • Biopharmaceutical / Biotechnology Companies
  • Pharmaceutical Companies
  • Academic & Research Institutes

Nucleic Acid Therapeutics CDMO Market By Therapeutic Area-

  • Oncology
  • Infectious Diseases
  • Rare Genetic Disorders
  • Cardiovascular & Metabolic Disorders
  • Neurological Disorders

Nucleic Acid Therapeutics CDMO Market By Region-

North America-

  • The US
  • Canada

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Chapter 1.    Methodology and Scope
1.1.    Research Methodology
1.2.    Research Scope & Assumptions

Chapter 2.    Executive Summary

Chapter 3.    Global Nucleic Acid Therapeutics CDMO Market Snapshot

Chapter 4.    Global Nucleic Acid Therapeutics CDMO Market Variables, Trends & Scope
4.1.    Market Segmentation & Scope
4.2.    Drivers
4.3.    Challenges
4.4.    Trends
4.5.    Investment and Funding Analysis 
4.6.    Industry Analysis – Porter’s Five Forces Analysis
4.7.    Competitive Landscape & Market Share Analysis
4.8.    Impact of Covid-19 Analysis

Chapter 5.    Market Segmentation 1: by Therapy / Modality Type Estimates & Trend Analysis
5.1.    by Therapy / Modality Type & Market Share, 2024  & 2034
5.2.    Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Therapy / Modality Type:

5.2.1.             mRNA-based Therapeutics
5.2.2.             DNA / Plasmid DNA Therapeutics
5.2.3.             siRNA (Small Interfering RNA)
5.2.4.             Antisense Oligonucleotides (ASOs)
5.2.5.             Gene Therapy Products
5.2.6.             Others

Chapter 6.    Market Segmentation 2: by Service Type Estimates & Trend Analysis
6.1.    by Service Type & Market Share, 2024  & 2034
6.2.    Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Service Type:

6.2.1.    Process Development & Optimization 
6.2.2.    Drug Product (Formulation, Fill & Finish)
6.2.3.    Analytical & Quality Control (QC) Services
6.2.4.    Regulatory Support & Technology Transfer
6.2.5.    Packaging & Fill–Finish Services

Chapter 7.    Market Segmentation 3: by Workflow Stage Estimates & Trend Analysis
7.1.    by Workflow Stage & Market Share, 2024  & 2034
7.2.    Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Workflow Stage:

7.2.1.    Preclinical Development
7.2.2.    Clinical Manufacturing (Phase I–III)
7.2.3.    Commercial-Scale Production

Chapter 8.    Market Segmentation 4: by End user Estimates & Trend Analysis
8.1.    by End user & Market Share, 2024  & 2034
8.2.    Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End user:

8.2.1.    Biopharmaceutical / Biotechnology Companies
8.2.2.    Pharmaceutical Companies
8.2.3.    Academic & Research Institutes

Chapter 9.    Market Segmentation 5: by Therapeutic Area Estimates & Trend Analysis
9.1.    by Therapeutic Area & Market Share, 2024  & 2034
9.2.    Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Therapeutic Area:

9.2.1.    Oncology
9.2.2.    Infectious Diseases
9.2.3.    Rare Genetic Disorders
9.2.4.    Cardiovascular & Metabolic Disorders
9.2.5.    Neurological Disorders

Chapter 10.    Nucleic Acid Therapeutics CDMO Market Segmentation 6: Regional Estimates & Trend Analysis
10.1.    North America

10.1.1.    North America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapy / Modality Type, 2021-2034
10.1.2.    North America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
10.1.3.    North America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Workflow Stage, 2021-2034
10.1.4.    North America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by End user, 2021-2034
10.1.5.    North America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic area, 2021-2034
10.1.6.    North America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

10.2.    Europe

10.2.1.    Europe Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapy / Modality Type, 2021-2034
10.2.2.    Europe Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
10.2.3.    Europe Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Workflow Stage, 2021-2034
10.2.4.    Europe Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by End user, 2021-2034
10.2.5.    Europe Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic area, 2021-2034
10.2.6.    Europe Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

10.3.    Asia Pacific

10.3.1.    Asia Pacific Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapy / Modality Type, 2021-2034
10.3.2.    Asia Pacific Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
10.3.3.    Asia-Pacific Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Workflow Stage, 2021-2034
10.3.4.    Asia-Pacific Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by End user, 2021-2034
10.3.5.    Asia Pacific Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic area, 2021-2034
10.3.6.    Asia Pacific Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

10.4.    Latin America

10.4.1.    Latin America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapy / Modality Type, 2021-2034
10.4.2.    Latin America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
10.4.3.    Latin America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Workflow Stage, 2021-2034
10.4.4.    Latin America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by End user, 2021-2034
10.4.5.    Latin America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic area, 2021-2034
10.4.6.    Latin America Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

10.5.    Middle East & Africa

10.5.1.    Middle East & Africa Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapy / Modality Type, 2021-2034
10.5.2.    Middle East & Africa Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service Type, 2021-2034
10.5.3.    Middle East & Africa Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Workflow Stage, 2021-2034
10.5.4.    Middle East & Africa Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by End user, 2021-2034
10.5.5.    Middle East & Africa Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic area, 2021-2034
10.5.6.    Middle East & Africa Nucleic Acid Therapeutics CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

Chapter 11.    Competitive Landscape
11.1.    Major Mergers and Acquisitions/Strategic Alliances
11.2.    Company Profiles


11.2.1.    Agilent Technologies, Inc.
11.2.2.    Bachem AG
11.2.3.    Ajinomoto Bio-Pharma Services
11.2.4.    BioSpring GmbH
11.2.5.    Exothera SA
11.2.6.    Helix Biotech
11.2.7.    LGC Group / Axolabs GmbH
11.2.8.    Thermo Fisher Scientific Inc. (Patheon)
11.2.9.    Danaher Corporation (Aldevron)
11.2.10.    WuXi AppTec Co., Ltd.
11.2.11.    Merck KGaA (MilliporeSigma Life Science)
11.2.12.    Curia Global, Inc. (formerly AMRI)
11.2.13.    KNC Laboratories Co., Ltd.
11.2.14.    Univercells / Univercells Technologies
11.2.15.    Integrated DNA Technologies (IDT, Danaher subsidiary)
11.2.16.    Evonik Industries AG (Health Care Business Line)
11.2.17.    Ology Bioservices (now part of National Resilience, Inc.)
11.2.18.    TriLink BioTechnologies (Maravai LifeSciences)
11.2.19.    AGC Biologics, Inc.
11.2.20.    Aurigene Pharmaceutical Services Ltd.
11.2.21.    PolyPeptide Group AG
11.2.22.    Eurofins Scientific SE (Eurofins Genomics Division)
11.2.23.    Kaneka Eurogentec S.A.
11.2.24.    Nitto Denko Avecia Inc. 
11.2.25.    ST Pharm Co., Ltd.
11.2.26.    Other Prominent Players

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
5016
Security Code field cannot be blank!

Frequently Asked Questions

Agilent Technologies, Inc., Bachem AG, Ajinomoto Bio-Pharma Services, BioSpring GmbH, Exothera SA, Helix Biotech, LGC Group / Axolabs GmbH, Thermo Fisher Scientific Inc. (Patheon), Danaher Corporation (Aldevron), WuXi AppTec Co., Ltd., Merck KGaA (MilliporeSigma Life Science), Curia Global, Inc. (formerly AMRI), KNC Laboratories Co., Ltd., Univercells / Univercells Technologies, Integrated DNA Technologies (IDT, Danaher subsidiary), Evonik Industries AG (Health Care Business Line), Ology Bioservices (now part of National Resilience, Inc.), TriLink BioTechnologies (Maravai LifeSciences), AGC Biologics, Inc., Aurigene Pharmaceutical Services Ltd., PolyPeptide Group AG, Eurofins Scientific SE (Eurofins Genomics Division), Kaneka Eurogentec S.A., Nitto Denko Avecia Inc., ST Pharm Co., Ltd., Others

Nucleic Acid Therapeutics CDMO Market Size is valued at USD 2,540.9 Million in 2024 and is predicted to reach USD 8,688.2 Million by the year 2034

Nucleic Acid Therapeutics CDMO Market is expected to grow at an 13.2 % CAGR during the forecast period for 2025-2034.

Therapy / Modality Type, Service Type, Workflow Stage, End-User and Therapeutic Area are the key segments of the Nucleic Acid Therapeutics CDMO Market.

North America region is leading the Nucleic Acid Therapeutics CDMO Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying